Labcorp has announced nationwide availability for the Agilent PD-L1 IHC 22C3 pharmDx, a critical companion diagnostic for identifying ovarian cancer patients eligible for Merck’s KEYTRUDA therapy.
Pfizer and Merck announce that the FDA has accepted a supplemental Biologics License Application (sBLA) for PADCEV in combination with KEYTRUDA for Priority Review in patients with muscle-invasive bladder cancer (MIBC).
Topline results from the Phase 3 BRUIN CLL-322 trial confirm that Jaypirca significantly extended progression-free survival when added to a venetoclax regimen.
AbbVie presented late-breaking Phase 2 data at SGO 2026 showing that Mirvetuximab Soravtansine PSOC treatment combined with carboplatin achieved a 62.7% response rate in FRα-high patients, offering a new hope for platinum-sensitive recurrence.
AstraZeneca announces positive results from the EMERALD-2 Phase III trial, proving that the Imfinzi and Imjudo liver cancer treatment significantly delays disease recurrence in patients following surgery or ablation.
GSK’s risvutatug rezetecan has officially secured Orphan Drug Designation from Japan’s MHLW for the treatment of small-cell lung cancer (SCLC). Supported by durable response data from the ARTEMIS-001 trial, this B7-H3-targeted antibody-drug conjugate aims to transform the prognosis for patients with extensive-stage disease, who currently face a median survival of just 8 months. This marks the sixth major global regulatory designation for risvutatug rezetecan, signaling its critical role in the future of oncology.
Atirmociclib Phase 2Â data released mark a potentially defining moment in the treatment of hormone receptor-positive metastatic breast cancer. Pfizer’s investigational CDK4 inhibitor demonstrated a statistically [Read More…]
Johnson & Johnson announces 89% complete response rate with Erda-iDRS for intermediate-risk non-muscle-invasive bladder cancer. First-in-human trial shows durable 18-month responses with tolerable safety profile.
While Roche’s persevERA trial didn’t meet its primary endpoint, the pharmaceutical company remains committed to advancing giredestrant as a new standard-of-care endocrine therapy. The FDA has accepted the company’s New Drug Application based on positive evERA data, signaling promise for this ER-positive breast cancer treatment.
Johnson & Johnson secures EC approval for AKEEGA® as the first precision-medicine combo for BRCA1/2-mutated metastatic hormone-sensitive prostate cancer, supported by landmark rPFS data from the AMPLITUDE trial.
